ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2

Meabco Inc, Chicago IL

Investigators

Abstract

The company plans to obtain FDA approval for BP-C2, a lignin-derived polyphenolic complex with ammonium molybdate, as a topical and/or oral treatment against injuries associated with cutaneous radiation syndrome.